Tuberous Sclerosis Global Clinical Trials Review, H2, 2016 - GlobalData

Tuberous Sclerosis Global Clinical Trials Review, H2, 2016

Tuberous Sclerosis Global Clinical Trials Review, H2, 2016 - GlobalData
Tuberous Sclerosis Global Clinical Trials Review, H2, 2016
Published Aug 31, 2016
74 pages — Published Aug 31, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GlobalData's clinical trial report, Tuberous Sclerosis Global Clinical Trials Review, H2, 2016' provides an overview of Tuberous Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Tuberous Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

  
Source:
Document ID
GDHC3715CTIDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Report Guidance51
Clinical Trials by Region67
  Clinical Trials and Average Enrollment by Country72
    Top Five Countries Contributing to Clinical Trials in Asia-Pacific91
    Top Five Countries Contributing to Clinical Trials in Europe101
    Top Countries Contributing to Clinical Trials in North America111
    Top Countries Contributing to Clinical Trials in Central and South America121
Clinical Trials by G7 Countries: Proportion of Tuberous Sclerosis to Genetic Disorders Clinical Trials131
Clinical Trials by Phase in G7 Countries141
Clinical Trials in G7 Countries by Trial Status151
Clinical Trials by E7 Countries: Proportion of Tuberous Sclerosis to Genetic Disorders Clinical Trials161
Clinical Trials by Phase in E7 Countries171
Clinical Trials in E7 Countries by Trial Status181
Clinical Trials by Phase192
  In Progress Trials by Phase201
Clinical Trials by Trial Status211
Clinical Trials by End Point Status221
Subjects Recruited Over a Period of Time231
Clinical Trials by Sponsor Type241
Prominent Sponsors252
  Top Companies Participating in Tuberous Sclerosis Therapeutics Clinical Trials261
Prominent Drugs271
Latest Clinical Trials News on Tuberous Sclerosis281
  Sep 06, 2016: Drug reduces seizure frequency in children with tuberous sclerosis complex281
Clinical Trial Profile Snapshots2942
Appendix713
  Abbreviations711
  Definitions711
  Research Methodology721
  Secondary Research721
  About GlobalData731
  Contact Us731
  Disclaimer731
Source741

Table Of Contents

GlobalData—GlobalData uses proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

About the Author


Cite this Report

  
MLA:
GlobalData. "Tuberous Sclerosis Global Clinical Trials Review, H2, 2016" Aug 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData/Tuberous-Sclerosis-Global-Clinical-Trials-Review-H2-2016-2085-23713>
  
APA:
GlobalData. (2016). Tuberous Sclerosis Global Clinical Trials Review, H2, 2016 Aug 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData/Tuberous-Sclerosis-Global-Clinical-Trials-Review-H2-2016-2085-23713>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.